The Patent Finder
KT

Karuna Therapeutics, Inc.

First filing 2019
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Eight patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2039. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2039
Next term end
3
Patent families

When these terms end

Each bar runs from grant to computed term end. 2021 to 2043.
US 10,933,020 Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation Sep 27, 2039
US 10,925,832 Compositions and Methods for Treatment of Disorders Ameliorated by Muscarinic Receptor Activation Sep 27, 2039
US 11,471,413 Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation Sep 27, 2039
US 11,452,692 Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation Sep 27, 2039
US 11,890,378 Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation Sep 27, 2039
US 12,558,317 Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation Oct 29, 2039
US 11,534,434 Xanomeline Derivatives and Methods for Treating Neurological Disorders Nov 16, 2040
US 12,421,242 Substituted Tetrahydropyrrolo-Pyridinone Compounds and Their Use in Treating Medical Conditions Dec 15, 2043
20262031203620412043
8 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Aug 6, 2027
    The maintenance fee for Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation (US 11,890,378) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 8 of 8

PatentTitleStatusExpiresConfidence
US 10,925,832Compositions and Methods for Treatment of Disorders Ameliorated by Muscarinic Receptor Activation
In force
 · High confidence
In forceHigh confidence
US 10,933,020Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
In force
 · High confidence
In forceHigh confidence
US 11,452,692Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
In force
 · Low confidence
In forceLow confidence
US 11,471,413Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
In force
 · Low confidence
In forceLow confidence
US 11,890,378Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
In force
 · Low confidence
In forceLow confidence
US 12,558,317Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
In force
 · Medium confidence
In forceMedium confidence
US 11,534,434Xanomeline Derivatives and Methods for Treating Neurological Disorders
In force
 · High confidence
In forceHigh confidence
US 12,421,242Substituted Tetrahydropyrrolo-Pyridinone Compounds and Their Use in Treating Medical Conditions
In force
 · Medium confidence
In forceMedium confidence
Also on record, not counted in the 8: 8 applications pending · 4 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited